Single best prognostic indicator of successful treatment with single-dose Methotrexate is
**Core Concept**
Methotrexate is a folate antagonist used in the treatment of various cancers and autoimmune diseases. Its efficacy is influenced by the level of dihydrofolate reductase (DHFR) activity in cancer cells, which is responsible for converting dihydrofolate to tetrahydrofolate, an essential precursor for DNA synthesis.
**Why the Correct Answer is Right**
The correct answer is related to the enzyme dihydrofolate reductase (DHFR). Methotrexate inhibits DHFR, thereby preventing the synthesis of tetrahydrofolate, which is crucial for DNA replication and cell division. The level of DHFR activity in cancer cells determines the effectiveness of methotrexate treatment. If DHFR activity is low, methotrexate can effectively inhibit DNA synthesis, leading to cell death. Conversely, high DHFR activity can render methotrexate treatment less effective.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not directly relate to the mechanism of action of methotrexate. While plasma protein binding can affect the distribution and elimination of methotrexate, it is not a direct indicator of treatment success.
* **Option B:** This option is incorrect because renal function, although important for methotrexate elimination, is not a direct indicator of treatment success with a single dose.
* **Option C:** This option is incorrect because it does not accurately reflect the mechanism of action of methotrexate. While folate levels can affect methotrexate efficacy, the direct indicator of successful treatment is the level of DHFR activity.
**Clinical Pearl / High-Yield Fact**
Remember that the efficacy of methotrexate is highly dependent on the level of DHFR activity in cancer cells. This is a critical factor to consider when choosing treatment options for patients with cancer.
**Correct Answer:** C. Low DHFR activity.